Purple Biotech Ltd. announced it has completed patient enrollment in a Phase 2 study of CM24, a multi-functional immune checkpoint inhibitor, for the treatment of pancreatic ductal adenocarcinoma (PDAC). The Phase 2 study (NCT04731467), in collaboration with Bristol Myers Squibb (BMS), is evaluating CM24 in combination with BMS's nivolumab plus chemotherapy in PDAC patients as a 2nd line treatment as compared to chemotherapy alone. The primary endpoint is overall survival (OS).

In patients treated with chemotherapy as a 2nd line treatment, the 5-year survival drops to 3%.